Search

UCB SA

Gesloten

SectorGezondheidszorg

174.45 0.23

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

171

Max

174.6

Belangrijke statistieken

By Trading Economics

Inkomsten

857M

Verkoop

3.4B

K/W

Sectorgemiddelde

31.43

39.857

Dividendrendement

0.83

Winstmarge

25.498

Werknemers

9,052

EBITDA

1.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.83%

2.42%

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.9B

33B

Vorige openingsprijs

174.22

Vorige sluitingsprijs

174.45

Nieuwssentiment

By Acuity

50%

50%

169 / 376 Rangschikking in Healthcare

UCB SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jul 2025, 23:34 UTC

Acquisities, Fusies, Overnames

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 jul 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 jul 2025, 21:04 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 jul 2025, 23:43 UTC

Marktinformatie

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 jul 2025, 22:47 UTC

Acquisities, Fusies, Overnames

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 jul 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 jul 2025, 22:46 UTC

Acquisities, Fusies, Overnames

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 jul 2025, 22:43 UTC

Acquisities, Fusies, Overnames

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 jul 2025, 22:43 UTC

Acquisities, Fusies, Overnames

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 jul 2025, 22:40 UTC

Acquisities, Fusies, Overnames

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:40 UTC

Acquisities, Fusies, Overnames

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:30 UTC

Marktinformatie
Winsten

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 jul 2025, 22:20 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

17 jul 2025, 22:20 UTC

Marktinformatie
Winsten

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 jul 2025, 22:04 UTC

Marktinformatie
Winsten

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 jul 2025, 22:03 UTC

Acquisities, Fusies, Overnames

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 jul 2025, 21:58 UTC

Marktinformatie
Winsten

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 jul 2025, 21:57 UTC

Winsten

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:47 UTC

Winsten

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 jul 2025, 21:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 jul 2025, 21:45 UTC

Marktinformatie

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 jul 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 jul 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 21:05 UTC

Winsten

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:04 UTC

Acquisities, Fusies, Overnames

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 jul 2025, 21:02 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 20:59 UTC

Acquisities, Fusies, Overnames

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

17 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

UCB SA Prognose

Koersdoel

By TipRanks

19.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 94.86Ā EURĀ  19.23%

Hoogste 125Ā EUR

Laagste 74Ā EUR

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor UCB SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

1

Hold

2

Sell

Sentiment

By Acuity

169 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.